Newsroom

New Data Show that UZEDY® Initiation in Hospitalized Patients is Associated with Faster Discharge and an Overall Clinician Preference Compared to Invega Sustenna®

September 22, 2025

September 22, 2025

New Pivotal Phase 3 Long-Term Data Supports Olanzapine Long-Acting Injectable (LAI) with Favorable Safety Profile – No PDSS Observed

September 22, 2025

September 22, 2025

Teva to Host Investor Call on Completed Phase 3 Olanzapine LAI Data Following Psych Congress 2025 Presentation

September 17, 2025

September 17, 2025

Appointment of Dr. Sharon Mates, Dr. Charles Kunsch, and Dr. Pascal Touchon to the Board of Directors

September 12, 2025

September 12, 2025

General Meeting 2025 (French)

September 11, 2025

UZEDY® Approved in South Korea

September 10, 2025

September 10, 2025

Medincell to Present at the H.C. Wainwright 27th Global Investment Conference and Participate in the Morgan Stanley 23rd Global Healthcare Conference

September 5, 2025

September 5, 2025

Improving in vivo release prediction from in situ forming depots with a novel flow-through in vitro dissolution apparatus

August 20, 2025

August 20, 2025

Notice of the 2025 Annual General Meeting Published

August 4, 2025

August 4, 2025

UZEDY® Accelerates: 2025 Revenue Outlook Raised to $190–$200M (from ~$160M); Olanzapine LAI on Track for Submission in 2025

July 30, 2025

July 30, 2025

Medincell Proposes Board Appointments of Dr. Sharon Mates and Dr. Charles Kunsch

July 29, 2025

July 29, 2025

Videoconference • Annual Results 2024-25

June 20, 2025